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Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL)
Promotes Angiogenesis and Ischemia-Induced Neovascularization Via
NADPH Oxidase 4 (NOX4) and Nitric Oxide–Dependent Mechanisms
Belinda Ann Di Bartolo, PhD; Sia^n Peta Cartland, PhD; Leonel Prado-Lourenco, PhD; Thomas Scott Grifﬁth, PhD; Carmine Gentile, PhD;
Jayant Ravindran, BMedSci; Nor SaadahMuhammad Azahri, PhD; Thuan Thai, PhD; AmandaWing Shee Yeung, PhD; Shane Ross Thomas, PhD;
Mary Meltem Kavurma, PhD
Background-—Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) has the ability to inhibit angiogenesis by inducing
endothelial cell death, as well as being able to promote pro-angiogenic activity in vitro. These seemingly opposite effects make its
role in ischemic disease unclear. Using Trail/ and wildtype mice, we sought to determine the role of TRAIL in angiogenesis and
neovascularization following hindlimb ischemia.
Methods and Results-—Reduced vascularization assessed by real-time 3-dimensional Vevo ultrasound imaging and CD31 staining
was evident in Trail/ mice after ischemia, and associated with reduced capillary formation and increased apoptosis. Notably,
adenoviral TRAIL administration signiﬁcantly improved limb perfusion, capillary density, and vascular smooth-muscle cell content in
both Trail/ and wildtype mice. Fibroblast growth factor-2, a potent angiogenic factor, increased TRAIL expression in human
microvascular endothelial cell-1, with ﬁbroblast growth factor-2-mediated proliferation, migration, and tubule formation inhibited
with TRAIL siRNA. Both ﬁbroblast growth factor-2 and TRAIL signiﬁcantly increased NADPH oxidase 4 (NOX4) expression. TRAIL-
inducible angiogenic activity in vitro was inhibited with siRNAs targeting NOX4, and consistent with this, NOX4 mRNA was reduced
in 3-day ischemic hindlimbs of Trail/ mice. Furthermore, TRAIL-induced proliferation, migration, and tubule formation was
blocked by scavenging H2O2, or by inhibiting nitric oxide synthase activity. Importantly, TRAIL-inducible endothelial nitric oxide
synthase phosphorylation at Ser-1177 and intracellular human microvascular endothelial cell-1 cell nitric oxide levels were NOX4
dependent.
Conclusions-—This is the ﬁrst report demonstrating that TRAIL can promote angiogenesis following hindlimb ischemia in vivo. The
angiogenic effect of TRAIL on human microvascular endothelial cell-1 cells is downstream of ﬁbroblast growth factor-2, involving
NOX4 and nitric oxide signaling. These data have signiﬁcant therapeutic implications, such that TRAIL may improve the angiogenic
response to ischemia and increase perfusion recovery in patients with cardiovascular disease and diabetes. ( J Am Heart Assoc.
2015;4:e002527 doi: 10.1161/JAHA.115.002527)
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A ngiogenesis is the growth of new blood vessels from apre-existing vessel bed by endothelial cells (ECs), an
essential physiological process for wound healing and
restoration of blood ﬂow after injury. Angiogenesis is
regulated by many factors, including vascular endothelial
growth factor (VEGF) and ﬁbroblast growth factor-1 and -2
(FGF-1 and FGF-2).1 A characteristic of many cardiovascular
diseases (CVDs) and diabetes is a deﬁciency of oxygen and
nutrients to tissues because of blocked or narrowed arteries.
Both VEGF and FGFs signiﬁcantly improve the angiogenic
response to ischemia.1 In spite of many clinical advances,
vascular occlusion and/or impairment of the microcirculation
puts patients at constant risk of ischemia, and the conse-
quent detrimental effects on quality-of-life and longevity.
Thus, new strategies that stimulate angiogenesis-regulating
factors to promote healing and restore blood ﬂow and oxygen
to tissues after ischemic injury are needed. These strategies
will be built on an understanding of the way in which
angiogenesis and neovascularization are regulated in CVD.
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Tumor necrosis factor (TNF)–related apoptosis-inducing
ligand (TRAIL) is a member of the TNF family of cytokines that
plays important roles in the cell-mediated immune response,
inﬂammation, and cellular processes up to and including cell
death.2–5 TRAIL was identiﬁed almost 20 years ago through
its high homology to TNF and Fas ligand, and has the ability to
promote apoptosis of cancer and transformed cells, while
having little-to-no cytotoxic activity on normal cells and
tissues.6,7 In humans, TRAIL signaling occurs upon binding
and trimerization of its receptors, DR4 and DR5. TRAIL
signaling in mice is similar, except only 1 murine TRAIL
receptor has been identiﬁed at the protein level, mDR5, which
has high sequence homology to DR4 and DR5. TRAIL/TRAIL-
receptors can also signal ERK1/2, mitogen-activated protein
kinase, c-Jun N-terminal kinase, and Akt—pathways that
promote survival, proliferation, migration, and differentiation
of normal cells.2,4,5
In CVD, TRAIL appears to be protective, such that
circulating TRAIL levels are reduced in patients with coronary
artery disease, acute coronary syndromes, myocardial infarc-
tion, and also in newly diagnosed type 2 diabetics.8–11 The
protective nature of TRAIL is further supported in rodent
models of atherosclerosis,12–14 pulmonary hypertension,15
and diabetes.12 At physiological levels, TRAIL stimulates
proliferation and survival of vascular smooth muscle cells
(VSMCs) in vitro and in vivo,16–18 but the role of TRAIL in
angiogenesis and EC function remains unclear. For example,
while TRAIL can inhibit angiogenesis by inducing EC
death,19,20 it can also promote angiogenesis in the chick
embryo chorioallantoic membrane model21 and EC prolifera-
tion, migration, and tubule formation in vitro.22 However,
there is no direct evidence for the role of TRAIL in regulating
angiogenesis in ischemic vascular diseases, and it is unknown
if TRAIL plays a pro- or anti-apoptotic role in this setting.
Using an in vivo model of angiogenesis where ischemia-
induced neovascularization of the hindlimb was induced in
Trail/ and wildtype mice, we provide the ﬁrst evidence to
suggest that TRAIL is important for FGF-2 and ischemia-
induced angiogenesis and EC function. Moreover, we describe
a new pathway involving TRAIL-dependent NADPH oxidase 4
(NOX4) and nitric oxide (NO) signaling in EC function relating
to angiogenesis in vitro. The potential clinical implications of
these ﬁndings will be discussed.
Methods
Mice
Trail/ mice were originally sourced from AMGEN and
provided by Mark Smyth from the Peter MacCallum Cancer
Centre (Melbourne, Australia). Trail/ mice were re-derived
at Australian BioResources (Moss Vale, NSW Australia; with
backcrosses equivalent to n10-16 in these experiments).
Wildtype C57Bl6 inbred mice were purchased from Australian
Resources Centre (ARC; Perth, Australia) and Australian
Biological Resources (Moss Vale, NSW, Australia). Mice were
monitored daily and used in speciﬁc pathogen-free conditions
with 12:12 hours light–dark cycles with free access to food
and water. All experiments were approved by the Animal Care
and Ethics Committee at The University of New South Wales
(Sydney, Australia) or the Sydney Local Health District Animal
Welfare Committee.
Hindlimb Ischemia
As previously described,23 female mice (8–12 weeks;
20–22 g) were anesthetized via inhalation of isoﬂurane, and
the surgical site was shaved and cleaned with saline. The
proximal and distal ends of the right femoral artery were
ligated, and the artery and all side branches were dissected
free along its entire length. The left hindlimb was used as a
sham. Neovascularization of the right and left hindlimbs was
evaluated by real time in vivo 3-dimensional imaging using the
Vevo Ultrasound (VisualSonics) and contrast agents (Vevo
MicroMarker Non-targeted contrast agent) at 28 days. Brieﬂy,
mice received a tail vein injection of contrast agent before
being anesthetized and placed on a heating platform.
Ultrasound gel was applied as a coupling interface between
the mouse and ultrasound probe; blood ﬂow measurements
were obtained via pulse imaging. Mice were anesthetized
using isoﬂurane and euthanized by cardiac exsanguination 3,
15, or 28 days after ischemic surgery. Arteriogenesis pre-
dominates close to the site of ligation (upper thigh muscle),
whereas angiogenesis predominates in the ischemic distal
bed (eg, gastrocnemius muscle). As such, the upper thigh and
gastrocnemius muscles were isolated at euthanasia.
Immunohistochemistry
To assess tissue architecture, hematoxylin and eosin staining
was performed in muscle tissue. Endothelial cell density was
conﬁrmed with CD31 immunostaining (1:50; Abcam) in the
gastrocnemius muscle. Digital images were captured using an
Olympus BX53 microscope. Vascular smooth muscle cell
content in the upper thigh was determined with smooth
muscle a-actin (1:2000; Sigma-Aldrich). Brieﬂy, parafﬁn-
embedded sections were de-waxed and subjected to antigen
retrieval. Following incubation with the primary antibody,
sections were mounted in ﬂuorescent mounting medium and
images were captured using a Zeiss Axio Imager Z2
microscope. All IgG controls were negative. At least 5 images
(920 magniﬁcation) were taken; CD31 and smooth muscle
a-actin–positive cells were counted/ﬁeld of view, by an
investigator blinded to treatment and genotype.
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Adenoviral Delivery
Murine Ad5TRAIL has been previously described24; Ad5LacZ
was used as a control. The Gene Transfer Vector Core at the
University of Iowa performed the expansion, puriﬁcation,
titration, and quality control of each virus. Ad5TRAIL or Ad5LacZ
(109 plaque-forming units) was injected into 2 sites within the
gastrocnemius muscle 2 days prior to ischemic surgery.
Laser Doppler
Hindlimb blood reperfusion was determined by laser Doppler
perfusion imaging (moorLDI2-IR, Moor Instruments). Imaging
was performed prior to surgery, then postsurgery at indicated
days.
Cell Death Detection ELISA
The Cell Death Detection ELISA (Roche) was used to detect
nuclear fragmentation and the release of histones according
to the manufacturer’s protocol. Prior to use of the kit, intact
nuclei from tissue were puriﬁed. Muscles were cut into small
pieces (1 mm2) and incubated in 0.1 mol/L citric acid
solution containing 0.5% Tween-20 for 20 minutes at room
temperature with moderate shaking. Samples were then
centrifuged (>523 g; 10 minutes) and 20 lL of the super-
natant was used in the ELISA, and normalized to mg tissue
used. Cultured human microvascular endothelial cell-1
(HMEC-1) were also assayed in accordance with the manu-
facturers’ instructions; absorbance (405–490 nm) was mea-
sured and normalized to total cell counts.
Cell Culture, Plasmids, and Reagents
HMEC-1 were obtained from the Centre for Disease Control
(MTA M1224I) and cultured in MCDB 131 medium (Gibco)
supplemented with 10% fetal bovine serum, hydrocortisone
(500 lg/mL Sigma-Aldrich), epidermal growth factor
(0.01 lg/mL Gibco), L-glutamine (2 mmol/L), and 5 U/mL
penicillin/streptomycin. Cells were not used beyond passage
40. All cells were maintained at 37°C in a humidiﬁed
atmosphere of 5% CO2. Unless indicated, 10 ng/mL recom-
binant human TRAIL (R&D Systems), 50 ng/mL human FGF-2
(Sigma Aldrich), 1 lmol/L L-NG-nitroarginine methyl ester (L-
NAME; Sigma Aldrich), and 200 U/mL PEG-catalase (Sigma
Aldrich) were used in all experiments.
Proliferation Assays
Total cell counts were measured using a Coulter Counter or the
Cell Countess (Invitrogen) where 2000 or 3000 cells/well were
seeded onto a 96-well plate. After 72 hours, the cells were
serum-arrested for 24 hours. Cells were then exposed to FGF-2
or TRAIL for a further 72 hours with or without L-NAME or
PEG-catalase added 1 hour prior to TRAIL or FGF-2 treatment.
For experiments involving siRNA, growth-quiescent HMEC-1
cells were transfected with 200 nmol/L pooled human TRAIL,
NOX4 (Santa Cruz Biotechnology), or AllStar control siRNA
(Qiagen) for 3 to 6 hours using FuGENE6 (Promega), prior to
the addition of TRAIL or FGF2 for 72 hours. Experiments were
performed with at least 3 to 4 replicates for each treatment per
independent experiment. Unless indicated, each experiment
was performed at least 3 times; the data from each indepen-
dent experiment were averaged and combined.
In Vitro Migration Assays
HMEC-1 cells were grown until a monolayer of cells was
formed. Cells were serum-arrested at conﬂuence in serum-
free MCDB 131 medium for 24 hours. Growth-quiescent
HMEC-1 cells were transfected with 200 nmol/L TRAIL,
NOX4, or AllStar control siRNA (siC) for 3 to 6 hours using
FuGENE6 (Promega), prior to scraping injury as previously
described.25 The medium was replaced followed by the
addition of TRAIL, FGF-2, or L-NAME and PEG-catalase.
Photographs of cells within the denuded area (94 magniﬁ-
cation) were captured 24 hours later using a Nikon Eclipse
TE2000-S microscope. Percentage of cellular regrowth in the
denuded zone was determined using Adobe Photoshop
Software (Adobe). Unless indicated, each experiment was
performed at least 3 times. Data from each independent
experiment were averaged and combined.
Tubule Assays
HMEC-1 cells were grown in 6-well plates. At 60% conﬂuency,
cells were serum-arrested for 24 hours followed by transfec-
tion with 200 nmol/L TRAIL, NOX4, or control siRNA using
FuGENE6. The following day, cells were trypsinized and
25 000 to 30 000 cells were seeded onto 100 lL Matrigel
(BD Bioscience) in 96-well ﬂat-bottom plates in serum-free
medium. At time of seeding, cells were treated with TRAIL,
FGF-2, L-NAME, and/or PEG-catalase. Photographs of tubules
(910 magniﬁcation) were taken 3 hours after plating using a
Nikon Eclipse TE2000-S microscope. The average length (lm)
of at least 30 tubules was quantiﬁed26 using NIH Image J
software. Unless indicated, each experiment was performed
at least 3 times. Data from each independent experiment
were averaged and combined.
Western Blotting
HMEC-1 cells at 60% conﬂuence in 6-well plates were serum
arrested for 24 hours. The cells were treated with TRAIL and/
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or FGF-2 for indicated times. The following day, cells were
lysed in 1X SDS Sample buffer (62.5 mmol/L Tris-HCl, pH
6.8, 10% glycerol, 2% SDS, 50 mmol/L dithiothreitol, and
0.1% bromophenol blue). Lysates were boiled (5 minutes,
100°C), centrifuged (5 minutes, 13 523 g) and proteins
separated using 7% Tris-acetate NuPAGE gels (Invitrogen).
Proteins were transferred onto nitrocellulose membrane using
the iBlot Gel Transfer System (Invitrogen). Membranes were
then incubated overnight at 4°C with rabbit polyclonal
phospho-endothelial nitric oxide synthase (eNOS) Ser(1177)
(1:1000, Cell Signaling Technology), mouse monoclonal eNOS
(1:1000, BD Biosciences), rabbit monoclonal NOX4 (1:1000,
Abcam), and mouse monoclonal a-tubulin (1:5000, Sigma-
Aldrich). Proteins were detected with horseradish peroxidase–
conjugated secondary anti-mouse or anti-rabbit antibodies
(Cell Signaling Technology) and visualized by chemilumines-
cence (Amersham, GE Healthcare Life Sciences). Densitom-
etry was performed using the lane analysis tools from NIH
ImageJ. Each experiment was performed at least 3 times.
Densitometry from each independent experiment was aver-
aged and combined.
Intracellular NO Detection by Confocal
Microscopy
Intracellular NO levels were assessed as described.27 Brieﬂy,
HMEC-1 cells in 8-well chamber slides (NUNC Lab-Tek,
Thermo Fisher Scientiﬁc) and at 60% conﬂuency were serum-
arrested for 24 hours. The cells were transfected with NOX4
or control siRNA using FuGENE6 for 24 hours. Cells were
pre-incubated with 2.5 lmol/L 4-amino-5-methylamino-
20,70-diﬂuoroﬂuorescein diacetate (DAF-FM diacetate; Invit-
rogen) for 30 minutes at 37°C, followed by the addition of
TRAIL for 15 minutes at 37°C. HMEC-1 cells were ﬁxed with
4% paraformaldehyde in PBS and imaged using a Zeiss LSM
510 Meta confocal microscope. Nuclei were stained with
CA
D
B
E
Figure 1. Trail/ mice have reduced vascularity following hindlimb ischemia. A, WT and Trail/ mice hindlimb after hindlimb ischemia. Top
panel, representative images showing necrotic toes of Trail/ mice at 14 days. Bottom panel, vascularization of the ischemic and
nonischemic hindlimbs were evaluated by real-time in vivo 3-dimensional Vevo ultrasound imaging using contrast agents (Vevo MicroMarker)
at 28 days (WT, n=5; Trail/, n=5). B, Apoptosis was assessed using the Cell Death Detection ELISA from muscle tissue 3 days after hindlimb
ischemia was induced; % apoptosis in ischemic muscle over control muscle (WT, n=3; Trail/, n=3). CD31 staining in gastrocnemius muscle
at (C) 3 days (WT, n=5; Trail/, n=4) and (D) 28 days postischemia (WT, n=5; Trail/, n=5). E, SMA staining at 28 days postischemia. Left
panel shows staining from ischemic leg. Right panel shows quantiﬁcation (WT, n=5; Trail/, n=4). Data were normalized to the nonischemic
control leg. Magniﬁcation bars=50 lm. Results are meanSEM; Mann–Whitney U-test; *P<0.05, **P<0.01, and ****P<0.0001. SMA
indicates smooth muscle a-actin; WT, wildtype.
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Hoechst stain (NucBlue Live ReadyProbesTM Reagent,
Invitrogen). DAF-FM diacetate ﬂuorescence was analyzed
by measuring the black:white ratio using ImageJ software
(NIH, Bethesda, MD) and normalized to nuclei count. Unless
indicated, each experiment was performed at least 3 times.
Data from each independent experiment were averaged and
combined.
RNA Extraction, cDNA Synthesis, and
Quantitative Polymerase Chain Reaction
Muscle was snap-frozen in liquid nitrogen at time of
euthanasia and stored at 80°C until further use. Tissues
were homogenized and RNA extracted using the ﬁbrous tissue
RNeasy kit (Qiagen). For studies involving HMEC-1 cells, at
60% conﬂuence, cells were serum-arrested for 24 hours
followed by TRAIL or FGF-2 treatment for an additional for
24 hours. Alternatively, serum-arrested HMEC-1 cells were
transfected with TRAIL, NOX4, or control siRNA using
FuGENE6 (Promega) for 3 to 6 hours, followed by the addition
of TRAIL or FGF-2. Total RNA was extracted with TRI reagent
as previously described.16 cDNA was generated using iSCRIPT
(Bio-Rad). Real-time quantitative polymerase chain reaction
was performed using the Rotor-Gene 6000 (Corbett Research)
or CFX96 (Biorad) and SensiFASTTM SYBR Kit (Bioline) in
quadruplicate. Relative changes in gene expression between
groups were determined using the 2ΔΔcT method. Values
were normalized to GAPDH or 18S, as indicated. Sequences
for human primers are as follows: GAPDH (forward 50- GAA
GGCTGGGGCTCATTT-3 and reverse 50-CAGGAGGCATTGCT-
GATGAT-30), TRAIL (forward 50-ACCAACGAGCTGAAGCAGAT-30
and reverse 50-CAAGTGCAAGTTGCTCAGGA-30), FGF-2 (forward
50-CAAAGCAGGAGGATCGCTTG-30 and reverse 50- GGCTCACT-
GAACCTTGACC-30), and NOX4 (forward 50- TGACGTTGCATCT
TTCAGGAG-30 and reverse 50-AGCTGGTTCGGTTAAGACTGAT-
30). NOX1 (forward 50-TTGTTTGGTTAGGGCTGAATGT-30 and
A C
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E F
Figure 2. Trail/ mice have reduced vascularity following hindlimb ischemia, which is rescued by TRAIL. A, TRAIL mRNA expression of the
gastrocnemius muscle after LacZ or TRAIL adenoviral delivery in Trail/ (LacZ, n=5; TRAIL, n=5) and (B) WT (LacZ, n=6; TRAIL, n=6) mice.
mRNA expression was normalized to 18S. C, LDPI showing improved limb perfusion in Trail/ mice administered TRAIL adenovirus vs LacZ at
15 days (left panel). Right panel shows quantiﬁcation (LacZ, n=5; TRAIL, n=5). D, Laser Doppler showing improved limb perfusion in WT mice
administered TRAIL adenovirus vs LacZ at 28 days (left panel). Right panel shows quantiﬁcation (LacZ, n=6; TRAIL, n=6). Capillary density (E) and
(F) VSMC content is elevated with TRAIL administration in Trail/ (LacZ, n=4; TRAIL, n=4) and WT (LacZ, n=4; TRAIL, n=6) mice. Data were
normalized to the nonischemic control leg. Results are meanSEM; Mann–Whitney U-test; *P<0.05, **P<0.01, and ****P<0.0001. LDPI
indicates Laser Doppler Perfusion Index; SMA, smooth muscle a-actin; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand; VSMC,
vascular smooth muscle cell; WT, wildtype.
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reverse 50-GCCAATGTTGACCCAAGGATTTT-30); NOX2 (forward
50-AGGGTCAAGAACAGGCTAAGGA-30 and reverse 50-TTCTCCA
CCTCCAACCCTCTTT-30). DR4 (forward 50- CCAACAAGACCTA
GCTCCCCAGC-30 and reverse 50-AAGACTACGGCTGCAACTGT-
GACTCC-30) and DR5 (forward 50-GTCCTGCTG CAGGTCGTA
CC-30 and reverse50-GATGTCACTCCAGGGCGTAC-30). Sequences
for murine primers are as follows: TRAIL (forward 50-GAA
GGCTGGGGCTCATTT-30 and reverse 50- CAGGAGGCATTGCT-
GATGAT-30), FGF-2 (forward 50-GTCACGGAAATACTCCAGTTG
G-30 and reverse 50-CCCGTTTTGGATCCGAGTT-30), NOX4 (for-
ward 50-CCCAAGTTCCAAGCTCATTTCC-30 and reverse 50-TG
GGACAGGTTTGTTGCTCCT-30), mDR5 (forward 50-GCAGAGAG
GGTATTGACTACACC-30 and reverse 50-GCATCGGGTTTCTAC-
GACTTT-30), VEGF-A (forward 50-TTACTGCTGTACCTCCACC-30
and reverse 50-ACAGGACGGCTTGAAGATG-30) and 18S
(forward 50- CGGCTACCACATCCAAGGAA-30 and reverse 50-
GCTGGAATTACCGCGGCT-30). Unless indicated, each experi-
ment was performed at least 3 times. Data from each
independent experiment were averaged and combined.
Statistics
GraphPad Prism version 5.0 or 6.0 (GraphPad Software, San
Diego, CA) was used to analyze data with results expressed as
meanSEM. Statistical comparisons were performed where
appropriate, using a Student t test, Mann–Whitney U-test, or
ANOVA (1- or 2-way with Bonferroni’s correction); P<0.05 was
considered signiﬁcant.
Results
TRAIL Is Required for Angiogenesis and
Arteriogenesis Following Hindlimb Ischemia In
Vivo
To investigate the role of TRAIL in ischemia-induced angio-
genesis, we used a mouse model of hindlimb ischemia
involving the unilateral ligation and removal of the femoral
artery.23 Functionally, Trail/ mice exhibited impaired
BA
DC
Figure 3. TRAIL-delivery stimulates TRAIL receptor expression. A, mDR5 expression of the gastrocnemius muscle in WT; (control, n=4;
ischemic, n=4) and Trail/ (control, n=4; ischemic, n=4) 3 days after hindlimb ischemia; control vs ischemic leg. Expression was normalized
to 18S. B, mDR5 expression is induced with adenoviral TRAIL in ischemic hindlimb of WT mice (right panel; LacZ, n=6; TRAIL, n=6), which is
not apparent in Trail/ mice (left panel; LacZ, n=4; TRAIL, n=5). Data were normalized to the nonischemic leg. C, DR4 but not (D) DR5
expression is increased with 24 hours TRAIL (10 ng/mL) treatment in HMEC-1 cells (n=4/treatment). Expression was normalized to GAPDH.
Results are meanSEM; 2-way ANOVA with Bonferroni comparisons, t test, or Mann–Whitney U-test *P<0.05, **P<0.01 and ****P<0.0001.
HMEC-1 indicates human microvascular endothelial cell-1; ns, not signiﬁcant; NT, no treatment; TRAIL, tumor necrosis factor-related
apoptosis-inducing ligand; WT, wildtype.
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recovery of limb movement and demonstrated increased limb
necrosis (Figure 1A, top panel). Consistent with this, signif-
icant inhibition of vascularization in Trail/ mice compared
to wildtype 28 days after induction of ischemia was observed
(Figure 1A, bottom panel), as revealed using contrast agents
and 3-dimensional Vevo ultrasound imaging. In addition,
ischemic hindlimb of these mice displayed elevated cellular
apoptosis (Figure 1B). CD31 staining of the gastrocnemius
muscle from ischemic hindlimb 3 days after surgery revealed
an 30% reduction in capillary density in Trail/ mice
compared to wildtype (Figure 1C). By day 28, Trail/ mice
displayed a further reduction in capillary density, 70%
(Figure 1D). The arteriogenic response, or the VSMC-driven
maturation of vessels, was also impaired after ischemia.
Similarly, smooth muscle a-actin staining in muscle demon-
strated reduced VSMC content (Figure 1E). Surprisingly, there
was signiﬁcant reduction in limb perfusion in Trail/ versus
wildtype mice, even prior to ischemic surgery (969.194.21
versus 661.394.68; P<0.05); this coincided with reduced
smooth muscle a-actin staining (3.730.58 versus
1.800.39; P<0.05), without affecting capillary density
(1.060.45 versus 0.360.18; P=0.15).
The importance of TRAIL in preventing the observed
pathology was demonstrated when TRAIL expression was
restored in Trail/ mice. TRAIL adenoviral delivery24,28
increased TRAIL expression in muscle (Figure 2A and 2B),
and signiﬁcantly improved limb perfusion in both genotypes
compared to mice that received the LacZ control adenovirus
(Figure 2C and 2D). This was not only associated with
signiﬁcantly increased capillary density (Figure 2E), but also
VSMC content (Figure 2F). Ischemia and TRAIL delivery also
augmented mDR5 expression in wildtype mice (Figure 3A
and 3B), with only DR4 mRNA increased with TRAIL
treatment in HMEC-1 cells in vitro (Figure 3C and 3D). In
contrast, ischemia and TRAIL-inducible mDR5 expression
was impaired with TRAIL-deﬁciency (Figure 3A and 3B).
These ﬁndings conﬁrm that TRAIL via death receptor
signaling not only promotes arteriogenesis, but is also a
crucial pro-angiogenic factor in ischemic vascular disease
in vivo.
BA C
D E F
Figure 4. The proangiogenic effects of FGF-2 are TRAIL dependent. A, FGF-2 increases TRAIL mRNA expression in ECs. HMEC-1 cells were
serum starved followed by FGF-2 (50 ng/mL) treatment for 24 hours prior to RNA extraction and real-time PCR. B, FGF-2 mRNA expression in
ECs was unchanged. HMEC-1 cells were serum starved followed by TRAIL (10 ng/mL) treatment for 24 hours prior to RNA extraction and real-
time PCR. TRAIL siRNA inhibits (C) FGF-2-inducible proliferation and (D) migration of ECs. Serum-arrested HMEC-1 cells were transfected with
200 nmol/L TRAIL siRNA or AllStar control siRNA (siC) for 3 to 6 hours prior to FGF-2 treatment. Total cell counts were assessed 72 hours later
and migration assessed 24 hours later. E, TRAIL siRNA blocks tubule formation inducible by FGF-2. Growth quiescent HMEC-1 cells were
transfected with siC or siTRAIL (200 nmol/L) overnight. Cells were then seeded into growth factor reduced Matrigel in serum-free media. Cells
were treated with FGF-2. Tubule formation was photographed and tubule length quantiﬁed. F, TRAIL siRNA inhibits TRAIL mRNA expression;
mRNA was normalized to GAPDH. Data represent the combined results of at least 3 independent experiments. Results are expressed as
meanSEM; t test or 1-way ANOVA with Bonferroni comparison; *P<0.05, **P<0.01 and ***P<0.001. ECs indicates endothelial cells; FGF-2,
ﬁbroblast growth factor-2; HMEC-1, human microvascular endothelial cell-1; NT, no treatment; PCR, polymerase chain reaction; TRAIL, tumor
necrosis factor–related apoptosis-inducing ligand.
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The Pro-Angiogenic Effects of FGF-2 in ECs are
TRAIL-Dependent
In our previous studies, TRAIL-inducible VSMC proliferation
and intimal thickening was dependent on FGF-2, with FGF-2
directly regulating transcription and expression of TRAIL in
these cells.17 TRAIL itself can also augment FGF-2 expres-
sion in VSMCs, suggesting an auto-regulatory loop.17
Treatment of ECs with FGF-2 resulted in signiﬁcantly
increased TRAIL mRNA expression (Figure 4A), consistent
with our ﬁndings in VSMCs.17 Unlike VSMCs,17 exposure of
ECs to TRAIL (10 ng/mL) did not inﬂuence FGF-2 expres-
sion (Figure 4B). We next assessed the importance of TRAIL
in FGF-2-induced EC functions. FGF-2-induced proliferation,
migration, and tubule formation was blocked with TRAIL
siRNA (Figure 4C through 4E), with TRAIL siRNA inhibiting
TRAIL mRNA by almost 40% under basal conditions
(Figure 4F). Consistent with these, FGF-2 expression from
ischemic gastrocnemius muscle of Trail/ mice was
reduced (Figure 5A) and increased following TRAIL adenovi-
ral delivery (Figure 5B and 5C). In contrast, we found VEGF
expression to be unaltered between Trail/ and wildtype
ischemic hindlimb (Figure 5D), nor was it induced with
TRAIL adenoviral delivery (not shown), suggesting that
TRAIL is not required for VEGFs effects in angiogenesis,
and our observations are speciﬁcally related to FGF-2 in
this setting.
TRAIL-Inducible EC Proliferation, Migration, and
Tubule Formation Involves NOX4
NOX4 is 1 of 7 NADPH oxidase (NOX) enzymes capable of
generating reactive oxygen species.29 While elevated reactive
oxygen species has the ability to cause oxidative stress,
trigger endothelial dysfunction, and initiate CVD,30 recent
studies indicate that NOX4 can exert protective actions on
cardiovascular function.31,32 We ﬁrst wanted to conﬁrm that
recombinant TRAIL itself could promote EC functions relating
to angiogenesis, and identify the extent of NOX4 involve-
ment. Recombinant human TRAIL treatment signiﬁcantly
increased EC proliferation over a concentration range of 10
A B
C D
Figure 5. TRAIL controls FGF-2 expression in vivo. A, Three days ischemic Trail/ (n=4) hindlimbs
express less FGF-2 mRNA compared to WT (n=4). B, FGF-2 mRNA expression of the gastrocnemius muscle
after LacZ or TRAIL adenoviral delivery in Trail/ (LacZ, n=5; TRAIL, n=5) and (C) WT mice (LacZ, n=6;
TRAIL, n=6) after hindlimb ischemia. D, Three days VEGF-A expression after hindlimb ischemia (WT, n=4;
Trail/, n=4). Results are a ratio of ischemic vs control gastrocnemius muscle. FGF-2 or VEGF-A was
normalized to 18S. Results are expressed as meanSEM; Mann–Whitney U-test; *P<0.05 and ***P<0.001.
FGF-2 indicates ﬁbroblast growth factor-2; ns, not signiﬁcant; TRAIL, tumor necrosis factor–related
apoptosis-inducing ligand; VEGF, vascular endothelial growth factor; WT, wildtype.
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to 400 ng/mL (Figure 6A and 6C), without inducing cell death
(Figure 6B). TRAIL at 10 ng/mL not only stimulated migration
of cells into the denuded zone 24 hours after scratch injury
(Figure 6D), but also promoted EC tubule formation (Fig-
ure 6E). Importantly, TRAIL-induced EC proliferation, migra-
tion, and tubule formation was attenuated with NOX4 siRNA
(Figure 6C through 6E), with NOX4 siRNA inhibiting basal
NOX4 mRNA by almost 40% (siC versus siNOX4; 1001.07
versus 65.356.15; P<0.001), and inhibiting TRAIL-inducible
NOX4 protein back to baseline (Figure 6F). Notably, NOX4
expression was signiﬁcantly reduced in the hindlimb of
ischemic Trail/ mice (Figure 7A). TRAIL also augmented
NOX4 mRNA and protein expression in HMEC-1 after
24 hours (Figure 7B and 7C), with no change in NOX1
(Figure 7D) or NOX2 (Figure 7E) mRNA. Consistent with our
ﬁnding, FGF-2 augmented NOX4 expression (Figure 8A), with
FGF-2-inducible proliferation, migration, and tubule formation
inhibited with siNOX4 treatment (Figure 8B through 8D).
Together, these data suggest a critical role for TRAIL (and
FGF-2) in NOX4-mediated EC function.
TRAIL regulates EC angiogenesis in vitro viaH2O2 andNO
The protective actions of NOX4 in CVD are, in part, due to its
ability to generate H2O2, since H2O2 can also stimulate cellular
proliferation in low doses.33 We next used PEG-catalase, a cell-
permeable scavenger of H2O2, to determine whether the
effects we were observing also involved H2O2. While treatment
of ECs with PEG-catalase alone had no effect on ECs (data not
shown), PEG-catalase blocked TRAIL-inducible EC proliferation
and migration (Figure 9A and 9B). TRAIL-induced tubule
formation was also inhibited with PEG-catalase treatment
(Figure 9C). Similar ﬁndings were observed with FGF-2 (Fig-
ure 9D through 9F). Thus, TRAIL regulates EC proliferation,
migration, and tubule formation, in part, by modulating H2O2.
Downstream of NOX4 and H2O2 signaling is eNOS phos-
phorylation and NO production, such that NOX4 itself can
stimulate eNOS phosphorylation under certain conditions.32
The NO pathway is essential for EC survival and proliferation27
and interestingly, both FGF-2 and TRAIL stimulate NO.22,34
Importantly, L-NAME, a competitive eNOS inhibitor, signiﬁcantly
A B
D E F
C
Figure 6. TRAIL-inducible proliferation, migration, and tubule formation involves NOX4. A, TRAIL stimulates EC proliferation at indicated
doses. Proliferation was assessed at 72 hours. B, TRAIL does not affect EC death. HMEC-1 cells were serum-starved for 24 hours followed by
TRAIL treatment. Apoptosis was assessed at 72 hours using a Cell Death Detection ELISA. C, siNOX4 inhibits TRAIL-inducible proliferation and
(D) migration. Growth-quiescent HMEC-1 cells were transfected with 200 nmol/L AllStar control (siC) and siNOX4 siRNA for 3 to 6 hours prior
to the addition of TRAIL (10 ng/mL). Cell counts were measured 72 hours later and migration was assessed 24 hours later. E, siNOX4 blocks
TRAIL-inducible tubule formation. Growth quiescent HMEC-1 cells were transfected with siC or siNOX4 (200 nmol/L) overnight. Cells were
then seeded into growth factor reduced Matrigel in serum-free media, and treated with 10 ng/mL TRAIL. Tubule formation was photographed
and quantiﬁed 3 hours later. F, siNOX4 inhibits TRAIL-inducible NOX4 protein expression at 24 hours. Western blotting for NOX4 protein
expression following siRNA and 10 ng/mL TRAIL treatment. The intensity of NOX4 expression compared to a-tubulin was determined by
densitometry (AU). Tubule data represent the combined results of 4 independent experiments. All other data represent the combined results of
3 independent experiments. Results are expressed as meanSEM; t test or 1-way ANOVA with Bonferroni comparison; *P<0.05, **P<0.01
and ***P<0.001. AU indicates arbitrary units; EC, endothelial cell; HMEC-1, human microvascular endothelial cell-1; NOX4, NADPH oxidase 4;
NT, no treatment; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand.
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reduced TRAIL-induced proliferation, migration, and tubule
formation (Figure 9A through 9C), with L-NAME alone having no
effect on EC function (data not shown). Similar ﬁndings were
observed in response to FGF-2 (Figure 9D through 9F). Not only
did 10 ng/mL TRAIL increase eNOS phosphorylation at
Ser-1177 as early as 2 minutes (Figure 10A), but TRAIL also
stimulated intracellular NO levels over a concentration range of
10 to 400 ng/mL (Figure 10B). To conﬁrm that theNOpathway
was playing a role in TRAIL-mediated effects, TRAIL-inducible
NOX4mRNA expression was inhibited by L-NAME (Figure 11A).
Furthermore, siRNA targeting NOX4, blocked TRAIL-induced
eNOS Ser-1177 phosphorylation (Figure 11B) and intracellular
NO production (Figure 11C). Together, these results conﬁrm
that TRAIL regulates EC functions relating to angiogene-
sis in vitro by modulating H2O2, eNOS phosphorylation at
Ser-1177, and NO production via NOX4.
Discussion
Angiogenesis is the growth of capillary networks consisting of
EC tubes, driven by hypoxia. Assessment of EC proliferation,
migration, and tubule formation is widely used as a model of
angiogenesis in vitro. Arteriogenesis, on the other hand, is the
maturation and stabilization of the newly formed blood
vessels by remodeling of VSMCs. In vitro, arteriogenesis is
characterized by differentiation, proliferation, and migration of
VSMCs and by remodeling of the extracellular matrix.
The data demonstrate for the ﬁrst time that TRAIL promotes
angiogenesis and arteriogenesis, thereby improving perfusion
in ischemic disease in vivo. First, TRAIL deﬁciency resulted in
reduced EC capillary density in the hindlimb ischemia-induced
neovascularization model—an established model of vascular
angiogenesis. Importantly, adenoviral-mediated delivery of
TRAIL not only rescued limb perfusion by increasing EC
density, but also by augmenting VSMC content following
ischemia. Second, we identiﬁed TRAIL to be a downstream
regulator of the angiogenic function of FGF-2 in HMEC-1 cells,
such that FGF-2-induced EC proliferation, migration, and
tubule formation was inhibited with siRNA technology target-
ing TRAIL. Third, we show that TRAIL-inducible EC effects
relating to angiogenesis in vitro involve NOX4. This is the ﬁrst
report linking TRAIL to NOX4 signaling, and as such, TRAIL-
induced EC proliferation, migration, and tubule formation
are dependent on H2O2 and eNOS-derived NO signals
(Figure 12A). Thus, TRAIL plays an adaptive and protective
role following ischemia-induced injury in the vessel wall.
A B
D E
C
Figure 7. TRAIL increases NOX4 expression. A, Three days ischemic Trail/ hindlimbs express less NOX4 mRNA compared to WT. Results
are expressed as a ratio of ischemic vs control gastrocnemius muscles 3 days after hindlimb ischemia. NOX4 expression was normalized to 18S
(WT, n=4; Trail/, n=4). B, NOX4 mRNA expression is increased with TRAIL treatment. Serum arrested HMEC-1 cells were treated with 10 ng/
mL TRAIL for 24 hours followed by qPCR. TRAIL expression was normalized to GAPDH. C, Western blotting demonstrating that TRAIL (10 ng/
mL) increases NOX4 protein expression over time in HMEC-1 cells. The loading control is represented by a-tubulin. The intensity of NOX4
expression compared to a-tubulin was determined by densitometry (AU). D, NOX1 and (E) NOX2 mRNA expression is unchanged with 10 ng/mL
TRAIL treatment. Expression was normalized to GAPDH. Unless stated, the data represent the combined results of at least 3 independent
experiments. Results are expressed as meanSEM; Mann–Whitney U-test, t test, or 1-way ANOVA with Bonferroni comparison; *P<0.05,
**P<0.01, and ***P<0.001. AU indicates arbitrary units; HMEC-1, human microvascular endothelial cell-1; NOX4, NADPH oxidase 4; NT, no
treatment; qPCR, quantitative polymerase chain reaction; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand; WT, wildtype.
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Following ischemia, both angiogenesis and arteriogenesis
occur simultaneously, and are important in generating func-
tional collateral networks necessary for effective blood
perfusion. While blood perfusion was reduced at baseline in
Trail/ mice, coinciding with reduced VSMC content in the
muscle, there was no difference in EC density between
genotype; a signiﬁcant reduction in EC density was only
observed following ischemic injury. These data imply that the
inherent changes to blood perfusion at baseline with TRAIL
deﬁciency involve impaired arteriogenesis rather than
angiogenesis. In contrast to the observed basal effects, here
we report TRAIL as a new player in facilitating a
pro-angiogenic response in vivo following ischemic injury.
Importantly, Trail/ mice displayed necrotic toes and
markedly impaired angiogenesis after hindlimb ischemia, with
TRAIL gene delivery signiﬁcantly improving blood perfusion via
increased capillary and VSMC content.
The effect of TRAIL on VSMC phenotype has been
extensively examined. We have shown that TRAIL can
promote VSMC proliferation, migration, and differentiation
in vitro and in vivo.12,14,16–18 Importantly, FGF-2 increases
TRAIL expression and TRAIL itself can regulate FGF-2
expression in cultured VSMCs. In support of this, FGF-2
expression, VSMC proliferation, and intimal thickening were
reduced in Trail/ mice in response to perivascular arterial
cuff placement.17 While TRAIL did not alter FGF-2 expression
in HMEC-1 cells in the current work, FGF-2 mRNA was
signiﬁcantly reduced in ischemic tissue from Trail/ mice,
and signiﬁcantly induced following TRAIL adenoviral delivery
in ischemic hindlimb of both genotypes. Our ﬁndings
A B
C D
Figure 8. FGF-2-inducible proliferation, migration, and tubule formation involves NOX4. A, FGF-2
increases NOX4 mRNA expression in ECs. HMEC-1 cells were serum starved followed by 50 ng/mL
FGF-2 for 24 hours prior to RNA extraction and real-time PCR. siNOX4 blocks FGF-2-inducible (B)
proliferation and (C) migration. Growth-quiescent HMEC-1 cells were transfected with 200 nmol/L
AllStar control (siC) and siNOX4 siRNAs for 3 to 6 hours prior to the addition of FGF-2 (50 ng/mL).
Cells counts were measured 72 hours later and migration assessed 24 hours later. D, siNOX4 blocks
FGF-2-inducible tubule formation. Growth-quiescent HMEC-1 cells were transfected with siC or
siNOX4 (200 nmol/L) overnight. Cells were then seeded in 100 lL of growth factor reduced Matrigel
and treated with 50 ng/mL FGF-2. Tubule formation was photographed and quantiﬁed 3 hours later.
Data represent the combined results of at least 3 independent experiments. Results are expressed as
meanSEM; 1-way ANOVA with Bonferroni comparison; *P<0.05, **P<0.01, ***P<0.001, and
****P<0.0001. ECs indicates endothelial cells; FGF-2, ﬁbroblast growth factor-2; HMEC-1, human
microvascular endothelial cell-1; NOX4, NADPH oxidase 4; NT, no treatment; PCR, polymerase chain
reaction.
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intriguingly imply that FGF-2 is both upstream and down-
stream of TRAIL in VSMCs, but only upstream of TRAIL
signaling in ECs. In contrast, no change in VEGF expression
was observed after ischemic injury, suggesting that VEGF’s
role in angiogenesis is unaffected by TRAIL deﬁciency and
may involve different mechanisms. A model for the role of
TRAIL in blood vessel formation is described in Figure 12B.
The data presented herein not only support our in vivo
ﬁndings, but also suggest a new pathway for TRAIL-mediated
effects on EC proliferation, migration, and tubule formation. In
contrast to the cytotoxic actions of TRAIL associated with
excessive reactive oxygen species production, our data
suggest that TRAIL has a protective, nonapoptotic effect in
EC biology. NOX enzymes are one of the most important
sources of reactive oxygen species in vascular cells, catalyz-
ing the transfer of electrons from NADPH to O2 via their NOX
subunit to generate O2
• ions.30 Multiple isoforms of NOX
have been identiﬁed (NOX1-5), with NOX1, 2, and 4 predom-
inantly expressed in ECs.30 Of note, TRAIL, DR4, and DR5 can
activate NOX1, increase intracellular O2
•⁻, and induce apop-
tosis.35 TRAIL can also stimulate membrane raft clustering,
co-localizing with DR4 and triggering NOX gp91phox subunit
aggregation36, implicating TRAIL in O2
•⁻ production via
NOX2.36 In our hands, TRAIL did not alter the expression of
NOX1 or 2, nor did we observe any detectable change in O2
•⁻
production by TRAIL in ECs (not shown). Instead, we show
that TRAIL-dependent EC proliferation, migration, and tubule
formation involves NOX4. Our ﬁndings are consistent with
other studies implicating NOX4, H2O2, and NO signaling in
angiogenesis. For example, angiogenic activity was attenu-
ated in NOX4-deﬁcient mice,31 while NOX4 overexpression
promoted perfusion and recovery in response to hindlimb
ischemia.32 EC-speciﬁc catalase transgenic mice also exhibit
signiﬁcantly reduced intracellular H2O2, eNOS activation, limb
perfusion, and capillary formation, with signiﬁcantly increased
tissue damage in response to hindlimb ischemia.37
The use of TRAIL as potential therapy to increase
angiogenesis and neovascularization would be a major
A B C
D E F
Figure 9. TRAIL and FGF-2-inducible proliferation, migration, and tubule formation involves H2O2 and NO. A, TRAIL-inducible proliferation and
(B) migration involves H2O2 and NO. Growth quiescent HMEC-1 cells were treated with PEG-Catalase (PEG-Cat; 200 U/mL) and L-NAME
(1 mmol/L) for 1 hour prior to 10 ng/mL TRAIL treatment. Cell counts were assessed 72 hours later and migration assessed 24 hours later. C,
TRAIL-inducible tubule formation involves H2O2 and NO. Serum-starved HMEC-1 cells were seeded in growth factor reduced Matrigel. Cells were
treated with TRAIL (10 ng/mL) and PEG-Cat (200 U/mL) or L-NAME (1 mmol/L). Tubule formation was photographed and quantiﬁed 3 hours
later. FGF-2-inducible (D) proliferation, (E) migration, and (F) tubule formation involves H2O2 and NO. Treatment with FGF-2 was identical to
above except that 50 ng/mL FGF-2 was used. Data represent the combined results of at least 3 independent experiments. Results are
expressed as meanSEM; 1-way ANOVA; *P<0.05, **P<0.01 and ***P<0.001. FGF-2 indicates ﬁbroblast growth factor-2; HMEC-1, human
microvascular endothelial cell-1; L-NAME, L-NG-nitroarginine methyl ester; NO, nitric oxide; NT, no treatment; TRAIL, tumor necrosis factor–
related apoptosis-inducing ligand.
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advantage in patients with CVD and diabetes. Unlike VEGF
and FGFs, which can promote tumor angiogenesis and tumor
growth,38,39 TRAIL kills tumor cells (even at 10 ng/mL40),
while leaving normal cells unaffected from its cytotoxic action.
Furthermore, its in vivo efﬁcacy, pharmacokinetics, and safety
are already known,41 and a number of TRAIL receptor agonists
are in clinical trials. Second, VEGF-induced angiogenesis may
need additional factors to help mature and stabilize collateral
vessels necessary to improve blood perfusion during ische-
mia. Indeed, newly formed vessels induced by VEGF can
appear primitive, disorganized, and lack stability.42 Delivery of
angiogenic and arteriogenic factors simultaneously in animal
models has resulted in synergistic angiogenesis with stable
vasculature structures, eg, VEGF in combination with FGF-2,
or with platelet-derived growth factor-B.43 We have shown
that TRAIL lies downstream of FGF-2 and platelet-derived
growth factor-B.16 While the mechanisms for TRAIL’s actions
in normal cells require further elucidation, our ﬁndings have
signiﬁcant therapeutic implications, such that TRAIL may
improve the angiogenic response to ischemia and increase
perfusion recovery in patients with cardiovascular disease and
diabetes. Thus, TRAIL monotherapy may represent a simpler
approach in promoting new and stable blood vessel networks
in ischemic disease.
A
B
Figure 10. TRAIL’s effects on eNOS and intracellular NO. A, 10 ng/mL TRAIL increases eNOS phosphorylation at Ser-1177 as early as
2 minutes after treatment of serum-arrested HMEC-1 cells. Total eNOS levels show loading. The intensity of eNOS phosphorylation at Ser-1177
compared to total eNOS was determined by densitometry (AU). B, TRAIL at indicated concentrations stimulate intracellular NO. DAF-FM
ﬂuorescence in green measuring intracellular NO levels; top and bottom panel represent duplicates. Nuclei were stained with Hoechst (blue).
Magniﬁcation bar=100 lm. Right panel, represents the quantiﬁcation. Control or NT. Western blotting data represent the combined results of at
least 3 independent experiments. Intracellular NO data represent the combined results of 2 independent experiments. Results are expressed as
meanSEM; 1-way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. AU indicates arbitrary units; DAF-FM, 4-amino-5-methylamino-
20,70-diﬂuoroﬂuorescein diacetate; HMEC-1, human microvascular endothelial cell-1; NO, nitric oxide; e-NOS, endothelial nitric oxide synthase;
NT, no treatment; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand.
DOI: 10.1161/JAHA.115.002527 Journal of the American Heart Association 13
TRAIL Promotes Angiogenesis Via NOX4 and NO Signals Di Bartolo et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on May 18, 2016http://jaha.ahajournals.org/Downloaded from 
AC
B
Figure 11. siNOX4 blocks TRAIL-inducible NO signaling. A, TRAIL-inducible (10 ng/mL) NOX4 mRNA expression is
inhibited with L-NAME. B, TRAIL-induced eNOS phosphorylation Ser-1177 at 15 minutes is blocked with siNOX4 (200 nmol/
L). Western blotting for p-eNOS(S1177) and a-tubulin showing unbiased loading. The intensity of eNOS phosphorylation at Ser-
1177 compared to a-tubulin was determined by densitometry (AU) (C) Left panel, TRAIL-inducible (10 ng/mL) intracellular
NO is inhibited by siNOX4 compared to the control siC. DAF-FM ﬂuorescence in green measuring NO levels; nuclei were
stained with Hoechst (blue). Right panel, quantiﬁcation of intracellular NO by HMEC-1 cells as described in the Methods
section. Magniﬁcation bar=100 lm. Data represent the combined results of at least 3 independent experiments. Results are
expressed as meanSEM; 1-way ANOVA with Bonferroni comparison; *P<0.05, **P<0.01, and ****P<0.0001. AU indicates
arbitrary units; DAF-FM, 4-amino-5-methylamino-20,70-diﬂuoroﬂuorescein diacetate; e-NOS, endothelial nitric oxide synthase;
HMEC-1, human microvascular endothelial cell-1; L-NAME, L-NG-nitroarginine methyl ester; NO, nitric oxide; NOX4, NADPH
oxidase 4; NT, no treatment; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand.
BA
Figure 12. Schematic for blood vessel formation inducible by TRAIL. A, FGF-2 and TRAIL-inducible
EC function relating to angiogenesis involves NOX4 and NO signaling. B, TRAIL delivery stimulates
blood vessel formation by modulating both EC and VSMC function to promote angiogenesis and
arteriogenesis. EC indicates endothelial cell; e-NOS, endothelial nitric oxide synthase; FGF-2,
ﬁbroblast growth factor-2; NO, nitric oxide; NOX4, NADPH oxidase 4; TRAIL, tumor necrosis factor–
related apoptosis-inducing ligand; VSMC, vascular smooth muscle cell.
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